These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23321661)

  • 21. Potential cost savings using GnRH agonists as preoperative therapy for uterine leiomyomas.
    Saltiel E
    Formulary; 1995 Sep; 30(9):532-4, 542. PubMed ID: 10161243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical management of recurrent aggressive angiomyxoma with gonadotropin-releasing hormone agonist.
    Shinohara N; Nonomura K; Ishikawa S; Seki H; Koyanagi T
    Int J Urol; 2004 Jun; 11(6):432-5. PubMed ID: 15157218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obesity and GnRH action. Report of a case with contribution by peripherally derived estrogens.
    Hansen LM; Batzer FR; Corson SL; Bello S
    J Reprod Med; 1997 Apr; 42(4):247-50. PubMed ID: 9131500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
    Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
    Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spontaneous expulsion of a uterine submucosal leiomyoma after administration of a gonadotropin-releasing hormone agonist.
    Yu KJ; Lai CR; Sheu MH
    Eur J Obstet Gynecol Reprod Biol; 2001 Jun; 96(2):223-5. PubMed ID: 11384814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas.
    Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M
    Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary medical management of recurrent aggressive angiomyxoma of the vulva with a gonadotropin-releasing hormone agonist.
    Fine BA; Munoz AK; Litz CE; Gershenson DM
    Gynecol Oncol; 2001 Apr; 81(1):120-2. PubMed ID: 11277663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of leiomyomas with gonadoliberin agonists].
    Puzigaca Z; Prelevic G; Markovic A
    Srp Arh Celok Lek; 2001; 129(5-6):143-6. PubMed ID: 11797463
    [No Abstract]   [Full Text] [Related]  

  • 29. Aborted leiomyosarcoma after treatment with leuprolide acetate.
    Mesia AF; Williams FS; Yan Z; Mittal K
    Obstet Gynecol; 1998 Oct; 92(4 Pt 2):664-6. PubMed ID: 9764655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Acute urinary retention in uterine myoma: description of a case].
    Melilli GA; Di Gesù G; Loizzi V; Vimercati A; Cormio G
    Arch Ital Urol Androl; 1998 Sep; 70(4):163-4. PubMed ID: 9823661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two cases of female acute urinary retention caused by an impacted pelvic mass.
    Hosokawa Y; Kishino T; Ono T; Oyama N; Momose H
    Int J Urol; 2005 Dec; 12(12):1069-70. PubMed ID: 16409615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An adenomyomatous polyp presenting as a large hypervascular tumor and its response to a gonadotropin-releasing hormone agonist.
    Lin YH; Chou YY; Huang LW; Seow KM; Hwang JL
    Taiwan J Obstet Gynecol; 2013 Mar; 52(1):129-30. PubMed ID: 23548234
    [No Abstract]   [Full Text] [Related]  

  • 33. Intermittent urinary retention secondary to a uterine leiomyoma.
    Barnacle S; Muir T
    Int Urogynecol J Pelvic Floor Dysfunct; 2007 Mar; 18(3):339-41. PubMed ID: 16788851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uterine artery embolisation for massive uterine fibroids in the presence of submassive pulmonary emboli.
    Boos CJ; Calver AL; Moors A; Dawkins KD; Hacking CN
    BJOG; 2005 Oct; 112(10):1440-2. PubMed ID: 16167954
    [No Abstract]   [Full Text] [Related]  

  • 35. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
    Crawford ED; Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Moul JW; Jensen JK; Olesen TK; Persson BE
    J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GnRH agonist therapy before myomectomy or hysterectomy.
    Gutmann JN; Corson SL
    J Minim Invasive Gynecol; 2005; 12(6):529-37; quiz 528, 538-9. PubMed ID: 16337584
    [No Abstract]   [Full Text] [Related]  

  • 37. Uterine fibroids, management and effect on fertility.
    Salman T; Davis C
    Curr Opin Obstet Gynecol; 2010 Aug; 22(4):295-303. PubMed ID: 20610997
    [No Abstract]   [Full Text] [Related]  

  • 38. [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone].
    Zeng C; Gu M; Huang H
    Zhonghua Fu Chan Ke Za Zhi; 1998 Aug; 33(8):490-2. PubMed ID: 10806751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced polyadenosine diphosphate-ribosylation in gonadotropin-releasing hormone agonist-treated uterine leiomyoma.
    Huang SC; Tang MJ; Cheng YM; Hsu KF; Ho CL; Chou CY
    J Clin Endocrinol Metab; 2003 Oct; 88(10):5009-16. PubMed ID: 14557488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
    Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.